Emerging Treatment Approaches and Multidisciplinary Management of Unresectable Stage III Non-Small Cell Lung Cancer - Episode 3
Optimizing Biomarker Testing for Unresectable Stage III NSCLC
This segment explores the role of biomarker testing in optimizing outcomes for non-small cell lung cancer (NSCLC), highlighting challenges in early-stage testing, the importance of multidisciplinary collaboration, and recent advances like the LAURA trial that emphasize the need for comprehensive biomarker assessment.
Video Player is loading.
Video content above is prompted by the following:
- Are you currently performing biomarker testing at your institution for patients with unresectable stage III NSCLC prior to treatment?
- If so, what does the process involve?
- Who is responsible for ordering the test (e.g., surgeons, medical oncologists, radiation oncologists)?
- How and when is testing typically conducted?
- Do you perform biomarker testing on blood as a complement to tissue testing?
Related Content:
